look at all the creeps.Stock does a normal consolidated and they sell.JUST WHAT THEY WANT.
$18 is a LOW price in the next 2 weeks
The numbers you post are all less than the selling by part of Fidelity.Only the top 4 will matter,but you will not get the info you are looking for/// the Institutions that bought the offering are not major owners.There was not one big player.Not one SEC document by one of the majors.Many offerings are gobbled up by insiders and this one was not so a flip may be in store.
A dilution of this magnitude will drive this stock down hard.The announced dilution was met with skepticism,but it was obvious///now we will see the result
There have been no regulatory or scientific peer review of the phase three results/ so no one including self
proclaimed experts have any information yet./ Mr Lewis may give the company's position and targets,but the
data analyzed by those in the scientific community and the regulatory bodies will decide the drugs
benefits ,side effects or lack thereof.
The data released is preliminary and yet to be discussed within the regulatory bodies or scientific community.Initial reaction is the drug works well with less severe patients and will be among choices but certainly not a "leader"as has been characterized here.This is not the indication that will make Insmed anything more than niche.NTM may.
Acting as if the transaction where insiders banks and BOD members got cheap shares is somehow shocking or surprising or illegal is new to bioteck stocks or the stock market in general.This is very normal.The initial takeover was far shadier but shareholders hold little sway against the above.Deal with it.Sell and move on.The SEC part is of no value and is fiction
only a few posts that should be ignored.Lewis is doing any better than any management team because money is flowing into his pockets.
I agree with the jist of your post,share your revenue and timeline projections.Where did you get those numbers? They are optimistic,if only for the fact that no NTM results are seen.